Drug Profile

Research programme: adenosine A3 selective antagonists - Domain Therapeutics

Alternative Names: DT 0522; DT 0738; FP 0522

Latest Information Update: 15 Jan 2014

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Faust Pharmaceuticals
Developer Domain Therapeutics
Class 3-ring heterocyclic compounds; Pyrroles; Quinoxalines; Small molecules
Mechanism of Action Adenosine A3 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

No development reported Asthma; Cancer; Chronic obstructive pulmonary disease; Glaucoma

26 Aug 2010 Pharmacodynamics data from a preclinical trial in Glaucoma presented at the 240th American Chemical Society National Meeting (2340th-ACS-2010)
20 Nov 2009 Domain Therapeutics' selective adenosine A3 antagonists programme for glaucoma is available for partnering (http://www.domaintherapeutics.com)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com